Episode 56: Thermo Fisher

Episode 62: Isomorphic Labs

Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medicines are discovered. We'll dive into the origins of AlphaFold, the scientific vision of Nobel Prize-winning CEO Demis Hassabis, how AI is reshaping medicinal chemistry, and why pharmaceutical giants like Novartis and Eli Lilly are investing billions in AI-powered drug discovery partnerships. We'll also discuss the promise, challenges, and future of foundation models in biology, and whether AI can truly accelerate the journey from molecule to medicine. Because the next blockbuster drug may not be discovered by chance, it may be designed by an algorithm. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #IsomorphicLabs #DeepMind #AlphaFold #ArtificialIntelligence #AI #DrugDiscovery #Biotech #Healthcare #PrecisionMedicine #Pharmaceuticals #MachineLearning #ProteinFolding #DemisHassabis #NobelPrize #MedicinalChemistry #LifeSciences #Biology #Google #Alphabet #EliLilly #Novartis #FutureOfMedicine #SciencePodcast #BiotechPodcast Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.

June 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 61: Danaher

Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Danaher became one of the biggest winners of the COVID-19 era. While biotech headlines focus on breakthrough drugs and billion-dollar acquisitions, Danaher quietly supplies the tools, diagnostics, manufacturing systems, and technologies that power modern medicine. From sequencing cancer genomes and producing monoclonal antibodies to manufacturing gene therapies and vaccines, Danaher sits behind the scenes enabling scientific innovation across the globe. We'll also discuss the leadership of Larry Culp, the company's role in the rise of biologics, gene therapies, and precision medicine, and the lessons Danaher offers about building value through infrastructure rather than blockbuster products. Because sometimes the companies changing healthcare aren't the ones discovering the drugs, they're the ones making discovery possible. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Danaher #Biotech #LifeSciences #Healthcare #Biopharma #Cytiva #PallCorporation #BeckmanCoulter #Diagnostics #GeneTherapy #CellTherapy #Biologics #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #LaboratoryScience #LarryCulp #BusinessPodcast #BiotechPodcast #HealthcareInnovation #Investing #Science #CorporateHistory #HealthcareBusiness Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 60: Hims & Hers

Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 59: Illumina

Send us Fan Mail [https://www.buzzsprout.com/2437458/fan_mail/new] In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show [https://www.buzzsprout.com/2437458/support] © 2026 The Perspective Bureau LLC. All rights reserved.